{"name": "Kymab",
 "permalink": "kymab",
 "crunchbase_url": "http://www.crunchbase.com/company/kymab",
 "homepage_url": "http://www.kymab.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "andrew.sandham@kymab.com",
 "phone_number": "+44 (0)1223 833301",
 "description": "",
 "created_at": "Mon Nov 01 02:54:38 UTC 2010",
 "updated_at": "Mon Nov 01 02:54:37 UTC 2010",
 "overview": "\u003Cp\u003EKymab Limited discovers, develops, and commercializes human therapeutic monoclonal antibodies for the treatment of human diseases using its proprietary Kymouse platform. Its platform captures the diversity of the B lymphocyte component of the human immune system and generates human antibody-based biopharmaceuticals directed against clinically precedented drug targets and drugs against novel targets. The company was incorporated in 2009 and is based in Cambridge, the United Kingdom.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       49],
      "assets/images/resized/0010/8059/108059v1-max-150x150.png"],
     [[198,
       65],
      "assets/images/resized/0010/8059/108059v1-max-250x250.png"],
     [[198,
       65],
      "assets/images/resized/0010/8059/108059v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Chairman \u0026 CEO",
    "person":
     {"first_name": "Andrew",
      "last_name": "P Sandham",
      "permalink": "andrew-p-sandham",
      "image": null}},
   {"is_past": false,
    "title": "Office Manager",
    "person":
     {"first_name": "Paulette",
      "last_name": "Alexander",
      "permalink": "paulette-alexander",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$30.4M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "http://www.kymab.com/docs/Kymab%20News%20Release%20v9%2008jul10.pdf",
    "source_description": "Kymab and Wellcome Trust sign \u00c2\u00a320 million financing to build a UK biopharmaceutical company based on human monoclonal antibody technology from The Sanger Institute",
    "raised_amount": 30400000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 7,
    "funded_day": 12,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Wellcome Trust",
         "permalink": "wellcome-trust",
         "image":
          {"available_sizes":
            [[[150,
               12],
              "assets/images/resized/0002/9701/29701v2-max-150x150.jpg"],
             [[250,
               20],
              "assets/images/resized/0002/9701/29701v2-max-250x250.jpg"],
             [[450,
               37],
              "assets/images/resized/0002/9701/29701v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Meditrina (B260)",
    "address2": "Babraham Research Campus",
    "zip_code": "CB22 3AT",
    "city": "Cambridge ",
    "state_code": null,
    "country_code": "GBR",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}